These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21852131)

  • 41. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.
    Sartipy P; Björquist P
    Stem Cells; 2011 May; 29(5):744-8. PubMed ID: 21433222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER
    Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):331-5. PubMed ID: 16623854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting myelosuppression of drugs from in silico models.
    Crivori P; Pennella G; Magistrelli M; Grossi P; Giusti AM
    J Chem Inf Model; 2011 Feb; 51(2):434-45. PubMed ID: 21275392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development.
    Ekins S; Williams AJ
    Lab Chip; 2010 Jan; 10(1):13-22. PubMed ID: 20024044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advances and novel strategies in pre-clinical formulation development: an overview.
    Shah AK; Agnihotri SA
    J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs.
    Wolfson W
    Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292
    [No Abstract]   [Full Text] [Related]  

  • 49. In vivo drug discovery in the zebrafish.
    Zon LI; Peterson RT
    Nat Rev Drug Discov; 2005 Jan; 4(1):35-44. PubMed ID: 15688071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening.
    Mahmoudi N; de Julián-Ortiz JV; Ciceron L; Gálvez J; Mazier D; Danis M; Derouin F; García-Domenech R
    J Antimicrob Chemother; 2006 Mar; 57(3):489-97. PubMed ID: 16415127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development.
    Festing MF
    Toxicol Pathol; 2010 Aug; 38(5):681-90. PubMed ID: 20562325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural product hybrids as new leads for drug discovery.
    Tietze LF; Bell HP; Chandrasekhar S
    Angew Chem Int Ed Engl; 2003 Sep; 42(34):3996-4028. PubMed ID: 12973759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthetic library design.
    Huwe CM
    Drug Discov Today; 2006 Aug; 11(15-16):763-7. PubMed ID: 16846805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 60. Preclinical drug development.
    Brodniewicz T; Grynkiewicz G
    Acta Pol Pharm; 2010; 67(6):578-85. PubMed ID: 21229871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.